Search

everythinglearnresearchcommunity

for

Search:↓

Biorregulatory therapy significantly improved the dog's health, reversing previous issues and eliminating the need for ongoing medication.

Diet can influence inflammatory skin diseases.

EGFR and MEK inhibitors reduce PD-L1 in hair follicles, possibly causing inflammation.

Dermal fibroblasts have adjustable roles in wound healing, with specific cells promoting regeneration or scar formation.

Platelet-released growth factors can reduce inflammation in joint disease.

NKIRAS2 can suppress certain skin tumors but its effect on cancer varies with context and expression level.

Patients with certain FoxN1 gene mutations have severe immune issues but normal skin and hair.

Antihepcidin antibodies may treat inflammation-induced anemia by improving iron metabolism.

Clonally expanded CD8+ T cells cause alopecia areata.

Hair loss in male pattern baldness is linked to changes in immune cell behavior around hair follicles.

Hair follicles could help develop eye treatments by studying immune responses.

Higher levels of MIG and IP-10 may help diagnose and monitor Alopecia Areata.

Activating TLR3 may help produce retinoic acid, important for tissue regeneration.

Monoclonal antibody B72.3 selectively reacts with certain dog tissues, mainly in the gastrointestinal and respiratory tracts.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

Autoimmune diseases cause the immune system to attack the body, and management varies as some are curable and others are not.

Autoimmune diseases cause the immune system to attack the body, and management varies as some are curable and others are not.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

New findings suggest potential treatments for melanoma, hyperpigmentation, hair defects, and multiple sclerosis, and show skin microbiome changes don't cause atopic dermatitis.

Machine learning can help find new ways to treat alopecia areata.

Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.

A patient's skin rash did not affect the area where a previous viral rash was healing, suggesting a rare immune response.

Activating liver X receptors can reduce fibrosis by stopping certain immune cells from releasing harmful proteins.

Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.

UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.

Finasteride increases CD8+ T cells in BPH tissues.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

Topical immunotherapy is still effective for managing alopecia areata, even with new treatments available.